Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Stearic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.69 |
| ▸ | PAM | P19021 | 2/20 | 0.62 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.61 |
| ▸ | PPARG | P37231 | 7/20 | 0.61 |
| ▸ | PPARD | Q03181 | 7/20 | 0.61 |
| ▸ | PPARA | Q07869 | 7/20 | 0.61 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.61 |
| ▸ | TSHR | P16473 | 4/20 | 0.61 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | TLR2 | O60603 | 2/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.61 |
| ▸ | FABP4 | P15090 | 2/20 | 0.61 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.61 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | ESR1 | P03372 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | PDE4A | P27815 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hexanoate SCHEMBL11510694 | 1.00 | DGKA (0.69) | DGKAPAMGPR84PPARGPPARD | |
| Dodecanoate SCHEMBL22365906 | 1.00 | DGKA (0.69) | DGKAPAMGPR84PPARGPPARD | |
| Hexane SCHEMBL7106975 | 0.98 | DGKA (0.66) | DGKAPAMGPR84PPARGPPARD | |
| SCHEMBL1443883 | 0.93 | DGKA (0.80) | DGKAPAMTSHRALDH1A1MEN1 | |
| SCHEMBL168967 | 0.93 | DGKA (0.80) | DGKAPAMTSHRALDH1A1MEN1 | |
| SCHEMBL23656812 | 0.93 | DGKA (0.80) | DGKAPAMTSHRALDH1A1MEN1 | |
| SCHEMBL2530608 | 0.93 | DGKA (0.80) | DGKAPAMTSHRALDH1A1MEN1 | |
| SCHEMBL825306 | 0.93 | DGKA (0.80) | DGKAPAMTSHRALDH1A1MEN1 | |
| SCHEMBL10412 | 0.93 | DGKA (0.80) | DGKAPAMTSHRALDH1A1MEN1 | |
| SCHEMBL3505311 | 0.93 | DGKA (0.80) | DGKAPAMTSHRALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883838-B2 | Pharmaceutical cream compositions and methods of use | ALLERGAN, INC. (US) | 2014-11-11 | — | — | US | claimed |
| US-20240189408-A1 | COMPOSITIONS AND METHODS FOR REDUCING METHANE EMISSIONS IN RUMINANT POPULATIONS | Arkea Bio Corp. | 2024-06-13 | — | — | US | disclosed |
| US-11931452-B2 | Topical compositions containing rofecoxib and methods of making and using the same | JF PHARMA TECH LLC (US) | 2024-03-19 | — | — | US | disclosed |
| WO-2024015366-A1 | COMPOSITIONS AND METHODS FOR REDUCING METHANE EMISSIONS IN RUMINANT POPULATIONS | Arkea Bio Corp. (US) | 2024-01-18 | — | — | WO | disclosed |
| US-20240009291-A1 | COMPOSITIONS AND METHODS FOR REDUCING METHANE EMISSIONS IN RUMINANT POPULATIONS | Arkea Bio Corp. | 2024-01-11 | — | — | US | disclosed |
| WO-2023187116-A1 | MIRABEGRON FORMULATION | Rheinische Friedrich-Wilhelms-Universität Bonn (DE) | 2023-10-05 | — | — | WO | disclosed |
| US-20230051811-A1 | RECTAL DELIVERY OF MESSENGER RNA | TRANSLATE BIO, INC. | 2023-02-16 | — | — | US | disclosed |
| US-20230000816-A1 | SODIUM-GLUCOSE LINKED TRANSPORTER INHIBITORS FOR THE MANAGEMENT OF CHRONIC KIDNEY DISEASE, HYPERTENSION, AND HEART FAILURE IN COMPANION ANIMALS | INCREVET, INC. | 2023-01-05 | — | — | US | disclosed |
| CN-115515559-A | Rectal delivery of messenger RNA | 翻译生物公司 | 2022-12-23 | — | — | CN | disclosed |
| EP-4023249-A1 | NUCLEIC ACID VACCINES | ModernaTX, Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
| US-20130184243-A1 | COMPOSITIONS OF ALKYLATING AGENTS AND METHODS OF TREATING SKIN DISORDERS THEREWITH | CEPTARIS THERAPEUTICS, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130123318-A1 | ANTI-FUNGAL FORMULATION | Topica Pharmaceuticals (US) | 2013-05-16 | — | — | US | disclosed |
| US-8362059-B2 | Anti-fungal formulation | Topica Pharmaceuticals, Inc. (US) | 2013-01-29 | — | — | US | disclosed |
| WO-2013009800-A2 | COMPOSITIONS OF ALKYLATING AGENTS AND METHODS OF TREATING SKIN DISORDERS THEREWITH | CEPTARIS THERAPEUTICS, INC. (US) | 2013-01-17 | — | — | WO | disclosed |
| US-8193232-B2 | Anti-fungal formulation | Topica Pharmaceuticals, Inc. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193233-B2 | Anti-fungal formulation | Topica Pharmaceuticals, Inc. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20120071533-A1 | ANTI-FUNGAL FORMULATION | Topica Pharmaceuticals, Inc. | 2012-03-22 | — | — | US | disclosed |
| US-20100210702-A1 | ANTI-FUNGAL FORMULATION | Topica Pharmaceuticals, Inc. (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100210703-A1 | ANTI-FUNGAL FORMULATION | Topica Pharmaceuticals, Inc. | 2010-08-19 | — | — | US | disclosed |
| WO-2010093992-A1 | ANTI-FUNGAL FORMULATION | TOPICA PHARMACEUTICALS, INC (US) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123318-A1 | ANTI-FUNGAL FORMULATION | DPM1, PIK3C3, SUCLG1 | DGKA 2307/4885PAM 3255/4885GPR84 4616/4885 |
| US-20130184243-A1 | COMPOSITIONS OF ALKYLATING AGENTS AND METHODS OF TREATING SKIN DISORDERS THEREWITH | MGMT, UNG, OGG1 | DGKA 2867/4885PAM 3411/4885GPR84 4718/4885 |
| US-20100210702-A1 | ANTI-FUNGAL FORMULATION | DPM1, PIK3C3, SUCLG1 | DGKA 2307/4885PAM 3255/4885GPR84 4616/4885 |
| US-20120071533-A1 | ANTI-FUNGAL FORMULATION | DPM1, PIK3C3, SUCLG1 | DGKA 2307/4885PAM 3255/4885GPR84 4616/4885 |
| US-20240009291-A1 | COMPOSITIONS AND METHODS FOR REDUCING METHANE EMISSIONS IN RUMINANT POPULATIONS | MT-CO2, CYB5R3, COX5A | DGKA 1229/4885PAM 808/4885GPR84 2305/4885 |
| US-20240189408-A1 | COMPOSITIONS AND METHODS FOR REDUCING METHANE EMISSIONS IN RUMINANT POPULATIONS | MT-CO2, CYB5R3, COX5A | DGKA 1229/4885PAM 808/4885GPR84 2305/4885 |
| US-20230000816-A1 | SODIUM-GLUCOSE LINKED TRANSPORTER INHIBITORS FOR THE MANAGEMENT OF CHRONIC KIDNEY DISEASE, HYPERTENSION, AND HEART FAILURE IN COMPANION ANIMALS | SLC5A1, SLC5A2, SLC2A1 | DGKA 4008/4885PAM 1794/4885GPR84 682/4885 |
| US-20100210703-A1 | ANTI-FUNGAL FORMULATION | DPM1, PIK3C3, SUCLG1 | DGKA 2307/4885PAM 3255/4885GPR84 4616/4885 |
| US-20230051811-A1 | RECTAL DELIVERY OF MESSENGER RNA | RNASE1, RNASEL, RNASEH1 | DGKA 3200/4885PAM 3433/4885GPR84 877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.